Myeloid-Derived Suppressor Cells Induce Podocyte Injury Through Increasing Reactive Oxygen Species in Lupus Nephritis

Dongya Zhang¹†, Jingjing Xu¹†, Jing Ren¹, Liang Ding¹, Guoping Shi¹, Dan Li¹, Huan Dou¹,²* and Yayi Hou¹,²*

¹The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China, ²Jiangsu Key Laboratory of Molecular Medicine, Nanjing, China

The expansion of myeloid-derived suppressor cells (MDSCs) has been documented in murine models and patients with lupus nephritis (LN), but the exact role of MDSCs in this process remains largely unknown. In this study, we investigated whether MDSCs are involved in the process of podocyte injury in the development of LN. In toll-like receptor-7 (TLR-7) agonist imiquimod-induced lupus mice, we found the severe podocyte injury in glomeruli of lupus mice and significant expansion of MDSCs in spleens and kidneys of lupus mice. The function of TLR-7 activated MDSCs was enhanced including the increased generation of reactive oxygen species (ROS) in vivo and in vitro. Moreover, the ROS production of MDSCs induced podocyte injury through activating the p-38MAPK and NF-kB signaling. Furthermore, we verified that podocyte injury was indeed correlated with expansion of MDSCs and their ROS secretion in LN of pristane-induced lupus mice. These findings first indicate that the podocyte injury in LN was associated with the increased MDSCs in kidney and MDSCs may be a promising therapeutic target of LN in the future.

Keywords: lupus nephritis, myeloid-derived suppressor cells, podocytes, toll-like receptor-7, reactive oxygen species

INTRODUCTION

Systemic lupus erythematosus (SLE) is a typical autoimmune disease and mostly occurs in females (9:1 prevalence) around child-bearing age (1). Lupus nephritis (LN), one of the most severe manifestations of SLE, is characterized by proteinuria, hematuria, and renal failure caused by deposition of immune complexes and tightly associated with high morbidity and mortality (2–4). Although there have been great advances in treatment and improved prognosis for patients with LN for over the past 30 years, LN treatment remains challenging. Indeed, only 50–70% of patients with LN achieved remission and 10–20% of patients will progress to end-stage renal disease within 5 years of diagnosis (5). In order to find an effective treatment, the detailed pathogenic mechanism of LN is still needed to be clarified.

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous collection of myeloid cells comprised myeloid precursors, immature granulocytes, mononuclear macrophages, and dendritic cells (6, 7). MDSCs are broadly characterized by CD11b⁺ Gr-1⁺ cells in mice and HLA-DR⁺CD11b⁺CD33⁺ cells in humans, which further divided into granulocytic polymorphonuclear MDSCs (G-MDSCs)
and monocytic MDSCs (M-MDSCs). G-MDSCs are phenotypically and morphologically similar to neutrophils, whereas M-MDSCs are similar to monocytes (8). Increasing evidence suggests that MDSCs exert a powerful influence on the regulation of autoimmunity in autoimmune diseases. It had been reported that MDSCs induced the expansion of regulatory B cells by inducible nitric oxide synthase (iNOS) to ameliorate autoimmunity in murine model of SLE (9). MDSCs suppressed the progression of collagen-induced arthritis by inhibiting the proinflammatory immune response of CD4+ T cells in autoimmune arthritis (10). The frequency of MDSCs was positively correlated with the levels of serum arginase-1 (Arg-1) activity, Thelper 17 (TH17) responses, and disease severity in SLE patients. In addition, MDSCs were essential for the associated renal injuries in a humanized SLE model (11). Recently, new evidence revealed that MDSCs play a crucial role in the regulation of LN. The granulocyte colony stimulating factor treatment ameliorated LN through reducing the number of G-MDSCs and M-MDSCs and promoting the preferential expansion of CD4+CD25+Foxp3+ Tregs in the spleen and kidney of NZB/W F1 female mice (12). Consistent with these results, in our previous study, the proportion of MDSCs in the kidney gradually increased along with the progression of SLE in MRL/lpr lupus-prone mice (13). Nevertheless, laquinimod suppressed LN in (NZB x NZW) F1 prone mice partly by inducing expansion of MDSCs and promoted a shift from proinflammatory type I monocyte/macrophages to anti-inflammatory type II monocyte/macrophages (14). These studies suggest that MDSCs may play a dual role in the development of LN. Although current evidence manifests that MDSCs are involved in LN, it is still unclear on their mechanisms in LN development.

Podocytes exert crucial influence on maintaining the normal renal function as the major component of the glomerular filtration barrier (15, 16). Podocyte injury is correlated with the generation of proteinuria, one of the major features of renal dysfunction in LN (17). Indeed, podocytes injury is common in patients with LN, as shown in a large cohort study of patients with renal-biopsy-proven LN (18). It had been reported the diverse mechanisms were involved in podocyte injury, including genetic factors, inflammation, toxic injury, and metabolic disturbances (19). Previous study revealed that the activated NLRP3 inflammasomes in podocytes from lupus-prone mice and LN patients was involved in the pathogenesis of podocyte injuries and the development of proteinuria in LN (20). Furthermore, oxidant stress-mediated aldosterone/MR-induced podocyte injury by triggering both Chop-dependent apoptosis and autophagy via activating ER stress (21). However, it has been unclear about the effect of MDSCs on podocyte injury in LN so far.

In the present study, we found that the significant expansion of MDSCs and severe podocyte injury in glomeruli of kidneys in toll-like receptor-7 (TLR-7) agonist imiquimod or pristane-induced lupus mice. Moreover, MDSCs generated the enhanced reactive oxygen species (ROS) via TLR-7 activation in vivo or in vitro, since TLR-7 is thought to trigger glomerulonephritis in experimental lupus erythematosus. Furthermore, the ROS production of MDSCs could induce podocyte injury through activating the p-38MAPK and NF-kB signaling. These results first indicate that the podocyte injury in LN was associated with the increased MDSCs in kidney and MDSCs may be a promising therapeutic target of LN in the future.

### MATERIALS AND METHODS

#### Mice

Female BALB/c mice (6–8 weeks old) and female C57BL/6 mice (6–8 weeks old) were obtained from Model Animal Research Center of Nanjing University (Nanjing, China) and kept under pathogen-free and housing conditions in a 12-h light and dark cycle. All experiments were conducted in accordance with institutional guidelines for animal care and used based on the Guide for the Animal Care Committee at Nanjing University. 10-week-old BALB/c mice received a single intraperitoneal injection of 0.5 ml pristane or PBS and monitored for the following 7 months. C57BL/6 mice were kept for 1 week. The skin on the right ears of the mice was treated topically, every other day, with 1.25 mg of 5% imiquimod cream for 10 weeks.

#### Cell Culture

The conditionally immortalized mouse podocyte cell line, MPC5 was purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co. (Shanghai, China). Cells were cultured at 33°C in RPMI-1640 medium (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS, Gibco BRL, Gaithersburg, MD, USA) and recombinant IFN-γ (PeproTech, USA). To induce differentiation, podocytes were reseeded and cultured at 37°C in 100 cm² culture dish coated with 12 mg/ml type-I collagen (BD Bioscience, Bedford, MA, USA) and in RPMI-1640 medium supplemented with 5% FBS, deprived of IFN-γ (growth restrictive conditions) for 10–13 days.

#### Histopathologic Analyses

Kidney tissues were fixed with 10% paraformaldehyde, embedded in paraffin, sectioned into 4-μm-thick slices, and stained with periodic acid–Schiff reagent.

#### Immunofluorescence Staining

Frozen sections of kidneys were stained with anti-CD11b (BD Pharmingen, USA) or anti-Gr-1 (BD Pharmingen, USA) followed by treatment with horseradish peroxidase-conjugated anti-rat IgG (Dako), and were visualized using diaminobenzidine (DAB) and hematoxylin as counterstaining. Frozen sections of kidneys were treated with anti-Wilms’ tumor protein (WT-1) (Merck Millipore, Bedford, MA, USA) or anti-Nephrin (Merck Millipore, Bedford, MA, USA), followed by treated with Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA). Sections were analyzed by laser scanning confocal microscope (FV3000, Olympus Corporation, Japan).

To investigate oxidative stress in the kidney tissues, DHE immunofluorescence staining was performed. Frozen, optimal cutting temperature-embedded kidney tissue was cryosectioned into 10-μm-thick sections, which were stained with 10 μmol/l dihydroethidium (DHE, Molecular Probes) solution (Invitrogen, Carlsbad, CA, USA). Images were obtained by laser scanning confocal microscope (FV3000, Olympus Corporation, Japan).
Isolation of MDSCs From Kidney and Spleen

Kidneys were cut into small fragments and digested to single-cell suspensions with 1 mg/ml collagenase type D (Roche) and 0.1 mg/ml DNase I (Roche) in HBSS (Hanks balanced saline solution) at 37°C for 30 min. The isolated cells were layered on a 30/40/75% Percoll gradient, followed by centrifugation for 20 min at 600 g, and collected the cells on the 40/75% interface, containing mostly leukocytes. After washing in FACS buffer, the cells were immediately processed for FACS.

Spleens were digested to single-cell suspensions with 1 mg/ml collagenase type D (Roche) and 0.1 mg/ml DNase I (Roche) in HBSS (Hanks balanced saline solution) at 37°C for 30 min. The cells were collected and suspended in ACK for the lysis of red blood cells and then centrifuge at 1,500 rpm for 5 min. After washing, cells were purified from spleen using magnetic-activated cell sorting beads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's protocol. The purity of cells after separation was >90%. Cells were then analyzed using flow cytometer (22).

Generation of BM-Derived MDSCs

BM cells were isolated as described previously from mice by flushing femurs and tibiae, and then BM cells were centrifuged and resuspended in culture medium supplemented with murine IL-6 and GM-CSF (both 40 ng/ml; Miltenyi Biotec, Auburn, CA, USA) and were cultured for 4 days (23, 24). Negative immune-selection of lineage-negative bone-marrow progenitors was performed using the Myeloid-Derived Suppressor Cell Isolation Kit.

Flow Cytometry Analysis

To detect mouse MDSC subsets, cell suspensions isolated from the spleens and kidneys were first incubated with Fc-blocker anti-CD16/32 antibody (dilution 1:20, Miltenyi Biotec) for 15 min, stained and pre-incubated with anti-CD11b-APC (1 µl/test) and anti-GR-1-PE (0.3 µl/test) for 30 min at 4°C in the dark. Cells were then washed with buffer to remove the excess stains and analyzed in a FACS (Becton Dickinson, San Diego, CA, USA). To detect TLR7 of MDSCs in pristane-treated mice, after stained with anti-CD11b-APC and anti-GR-1-PE, fixed and permeabilized by BD Fixation/Permeabilization Solution Kit (BD Pharmingen, USA), stained with anti-TLR7-FITC (Invitrogen, USA) for 30 min at 4°C.

Apoptosis Assay

Podocyte apoptosis was measured by flow cytometry using an annexin V-FITC apoptosis detection kit (Becton Dickinson, San Diego, CA, USA). Briefly, podocytes were collected and suspended in 500 µl binding buffer, followed by staining with annexin V-FITC and propidium iodide (PI) at room temperature for 5 min in the dark. After removing the unbound annexin V-FITC and PI by centrifugation, the cells were resuspended in excess binding buffer. For each measurement, at least 10,000 cells were analyzed by FACS flow cytometer (Becton Dickinson, San Diego, CA, USA).

ROS Detection

The oxidation-sensitive dye DCFDA (Beyotime, Shanghai, China) was used to measure ROS production. Cells were incubated at 37°C in RPMI in the presence of 2.5 µM DCFDA for 30 min. Then cells were simultaneously cultured, along with DCFDA, with 1 µg/ml LPS (Sigma-Aldrich, Louis, USA) before detected by flow cytometer (Becton Dickinson, San Diego, CA, USA) (25).

Western Blot Analysis

Western blot analysis was performed as described previously. The podocytes, MPC5 cells were lysed in buffer containing 50 mmol/l Tris–HCl, pH 8.0, 150 mmol/l NaCl, 0.02% Na3, 0.1% SDS, 100 mg/l phenylmethylsulfonyl fluoride, 1 mg/l aprotinin, and 1% Triton. Cell extract was separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked for 1 h in TBST (10 mmol/l Tris–HCl, pH 7.4, 150 mmol/l NaCl, 0.05% Tween-20) containing 5% bovine serum albumin, incubated with primary antibodies (Merck Millipore, Bedford, MA, USA), WT-1 (Merck Millipore), p-p38MAPK [Cell Signaling Technology (CST), Danvers, MA, USA], p-38MAPK (CST), p-p65 (CST), p-65 (CST), and GAPDH (CST) at 4°C overnight and then incubated with secondary antibodies. Bands were visualized with enhanced chemiluminescence reaction (Millipore Corp.). GAPDH was used as the loading control. Protein bands were captured and analyzed using the Lane 1D software (Sage Creation Science Co., Beijing).

Reverse Transcription and Real-Time Quantitative PCR Analysis

Total RNA was isolated from cells or tissues using TRizol reagent (Invitrogen) according to the manufacturer's instructions. The condition of reversed transcription for cDNA with reverse transcription system was 42°C for 5 min, 99°C for 20 min, and 4°C for 5 min. The SYBR Green PCR Master Mix (Bio RAD) according to the manufacturer's instructions was performed for quantitative real-time RT-PCR (qRT-PCR). The qPCR assays were carried out on a Step One Plus, and data collected with this instrument. Relative gene expression was calculated with the 2−ΔΔCt formula, and results were normalized to the expression of GAPDH. All the primer sequences are shown in Table S1 in Supplementary Material.

Statistical Analysis

All statistical calculations were performed using commercially available statistical software GraphPad Prism (GraphPad, San Diego, CA, USA). Results were expressed as mean ± SEM of three independent experiments and each experiment included triplicate sets. Data were statistically evaluated by one-way ANOVA followed by Dunnett's test between control group and multiple dose groups. Statistical significance was defined at equal to or more than 95% confidence interval or P ≤ 0.05.

RESULTS

Podocyte Injury in TLR-7 Agonist Imiquimod-Induced Lupus Mice

It has been report that TLR-7 is involved in the development of SLE (26). The up-regulation of TLR-7 in patient with SLE and TLR-7 activation in wild-type mice leads to lupus-like systemic autoimmune disease with elevated levels of autoantibodies and multiple organ involvement (27, 28). According to previous study...
(28), we initially applied imiquimod (IMQ), a TLR-7 agonist, to induce lupus mice. Consistent with previous report, the spleens of IMQ-treated mice became swollen (Figure 1A) and significant changes have been found in renal morphology (Figure 1B). Moreover, the level of urinary protein was significantly higher in urine of IMQ-treated mice than in normal controls (Figure 1C).

Furthermore, WT-1 and nephrin are required during kidney development for the maturation of podocytes and their expressions are down-regulated in acquired glomerular diseases. The deficiency of WT-1 and nephrin is considered a pathologic feature of glomerular injury. The analysis of immunofluorescence showed that the expression of WT-1 and nephrin was obviously decreased in kidney of IMQ-treated mice compared with wild mice (Figures 1D,E). The down-regulated expression of WT-1 and nephrin at mRNA level was confirmed by qRT-PCR (Figures 1G,H). Meanwhile, electron microscopy revealed that the foot process effacement of podocyte was exacerbated in the IMQ-treated mice compared with wild mice. These results indicated that podocyte injury of the glomerulus was obviously more serious in TLR-7 agonist imiquimod-induced lupus mice than normal mice.

**Expansion of MDSCs Correlates Positively With Podocyte Injury in Imiquimod-Induced Lupus Mice**

Previously, we found significant expansion of MDSCs in lupus mice, and expanded MDSCs correlated positively with disease severity in diseased lupus-prone mice (13). Here, we verified the percentage of MDSCs in kidneys and spleens by flow cytometry again, and the results showed the frequency of MDSCs markedly elevated in both kidneys and spleens of IMQ-treated mice compared with wild-type mice (Figures 2A,B). We further examined whether the expansion of MDSCs was associated with the decreased expression of WT-1 and nephrin. The results showed the expanded MDSCs were negatively correlated with the reduced expression of WT-1 and nephrin at mRNA level (Figures 2C,D). Expectedly, the function of MDSCs was also changed, i.e., the expression levels of their functional genes, including NOX component P47phox, iNOS, and Arg-1 were evidently increased in MDSCs purified from kidneys and spleens of IMQ-treated mice (Figures 1E,F and 2E,F). These results indicate the expanded MDSCs correlated positively with renal...
Figure 2 | Expansion of myeloid-derived suppressor cells (MDSCs) in IMQ-treated mice. (A, B) The frequency of renal (A) and splenic (B) MDSCs in wild mice and IMQ-treated mice were determined by FACS, right panel is the statistics for the results of flow cytometry. (C, D) Correlation analysis between mRNA of Wilms' tumor protein (WT-1) (C), nephrin (D), and the frequency of MDSCs in IMQ-treated mice. Each symbol represents an individual mouse (WT-1: n = 16, r² = 0.5797, P = 0.0006; nephrin: n = 16, r² = 0.5168, P = 0.0014). (E) Expression of P47phox, inducible nitric oxide synthase, and arginase-1 in MDSCs purified from kidneys of wild mice and IMQ-treated mice was measured by quantitative real-time RT-PCR (qRT-PCR). (F) Expression of functional molecules from splenic MDSCs of wild mice and IMQ-treated mice was determined by qRT-PCR. Data represent the mean scores ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
injury severity in the inducible lupus murine model and may be involved in podocyte injury of nephropathy damage process in LN.

**TLR-7-Activated MDSCs Induce Podocyte Injury In Vitro**

To explore the specific role of MDSCs in podocyte injury, we respectively incubated podocytes alone as control group, treated podocytes with R848 as positive group, co-cultured podocytes with BM-induced MDSCs by transwells in vitro, stimulated with or without resiquimod (R848), a TLR-7 agonist. The results showed that most significant change was observed in the live podocytes co-cultured with R848-stimulated MDSCs, while morphologic change was also observed in co-cultured group of MDSCs. But no change was observed in control group and positive control group (Figure 3A). Moreover, the significant reduced expression of WT-1 and nephrin, two molecular

**FIGURE 3** Toll-like receptor-7 (TLR-7)-activated myeloid-derived suppressor cells (MDSCs) induce podocyte injury. BM-derived MDSCs were co-cultured with mouse podocytes at ratio of 1:1 using transwell co-culture systems. (A) Representative light photomicrographs of podocytes after 48 h co-culture with MDSCs. (B,C) Expression of Wilms’ tumor protein (WT-1) (B) and nephrin (C) in podocytes was determined by immunofluorescence after 48 h co-culture with MDSCs. (D,E) Expression of nephrin and WT-1 in podocytes was determined by quantitative real-time RT-PCR (qRT-PCR) after 24 h co-culture with MDSCs (D) and Western Blot for nephrin and WT-1 after 48 h co-culture with MDSCs (E). (F) Expression of desmin and vascular endothelial growth factor in podocytes was determined by qRT-PCR after 24 h co-culture with MDSCs. (G) Podocyte apoptosis was assessed with Annexin V and propidium iodide by flow cytometry after 48 h co-culture with MDSCs. (H) Expression of IL-1β, IL-6, and TNF-α in podocytes was measured by qRT-PCR after 24 h co-culture with MDSCs. Data represent the mean scores ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
markers of podocytes, was determined by immunofluorescence in the co-cultivation group of podocytes and R848-stimulated MDCs (Figures 3B,C). In consistence with these results, the expression of WT-1 and nephrin was also manifestly decreased at both mRNA level and protein levels in the co-cultured group of podocytes and R848-treated MDCs (Figures 3D,E). In addition, the expression of desmin, which is a sensitive marker of podocyte injury (29), was up-regulated at mRNA level in the co-cultured podocytes and R848-treated MDCs, compared to control groups (Figure 3F). As previous study shown, podocytes can also secrete vascular endothelial growth factor (VEGF) to maintain the integrity of glomerular endothelial cells and promote the formation of new capillaries (17). The expression of VEGF was measured by qRT-PCR and the results showed that the down-regulated expression of VEGF in podocytes co-cultured with R848-treated MDCs (Figure 3F). These data reveal that TLR-7-activated MDCs indeed induce podocyte injury in vitro.

To further directly investigate the association of TLR-7-activated MDCs with podocyte injury. We measured the cell apoptosis of podocytes alone, R848-treated, co-cultured with MDCs stimulated with or without R848 using transwell by flow cytometer, respectively. The results showed that MDCs treated with R848 promoted obviously podocytes apoptosis, compared with the treatment of podocytes alone (Figure 3H). Moreover, the expression of inflammatory factors, such as IL-1β, IL-6, and TNF-α were up-regulated markedly in podocytes co-cultured with MDCs treated with R848 (Figure 3G). These results indicate TLR-7-activated MDCs can cause podocyte apoptosis and induce podocytes to secrete inflammatory factors.

Podocyte Injury Is Attributed to ROS From TLR-7-Activated MDCs

To elucidate the mechanism of TLR-7-activated MDCs impair podocytes, we focused on functional molecules of MDCs. The results showed that the functional molecules of MDCs were significantly up-regulated in a dose-dependent effect of TLR-7 agonist R848 treatment (Figures 4A–C). The function of MDCs was also enhanced by activating TLR-7 signaling. Previous study revealed that renal overexpression of ROS could directly lead to podocyte injury in diabetic nephritis model mice and increased production of oxidative stress markers in the renal tissue of SLE patients (30, 31). To further determine the role of the functional molecule of MDCs in podocyte injury, we co-cultured podocytes with MDCs treated with R848, or pretreated with ROS inhibitors N-acetyl-L-cysteine (NAC) or iNOS inhibitors L-NMMA for 1 h before treated with R848. The results showed that the expression of WT-1 and nephrin was increased, while the expression of IL-1β, IL-6, and TNF-α was reduced in podocytes co-cultured with MDCs pretreated with NAC before treatment with R848, compared with control group, and co-cultured with MDCs treated with R848 (Figure 4D). In neutralizing iNOS using L-NMMA, podocyte injury and the levels of inflammatory factors were not significantly alleviated (Figure 4E). The results indicated that podocyte injury may be attributed to ROS generation from TLR-7-activated MDCs.

ROS Promotes Podocyte Injury via p-38MAPK and NF-κB Signaling

To verify further the effect of ROS secreted by MDCs on podocyte injury, apoptosis of podocytes was tested. We first observed that podocytes became shrinking and round in cellular morphology when co-cultured with MDCs treated with R848. In contrast, the change in podocytes was reversed when co-cultured by adding R848 to MDCs after pretreated with NAC for 1 h (Figure 5A). Moreover, we detected podocyte injury marker desmin and cell apoptosis after co-incubated with R848-treated MDCs following NAC-pretreatment. The results showed that NAC-pretreatment significantly reduced expression of desmin (Figure 5B). In consistence with the results, NAC-pretreatment obviously decreased the cell apoptosis of podocytes (Figures 5C,D). These results indicate that inhibition of ROS by NAC markedly blocked the deteriorative effect of MDCs on podocyte injury. In addition, previous studies have shown that ROS might promote podocyte injury via activation of p-38MAPK or NF-κB pathway (32, 33). Thus, we measured the protein expression of p-p38MAPK, p-38MAPK, p-p65, and p-p65 by Western blot. The results showed that the expressions of p-p38MAPK and p-p65 were significantly increased in podocytes co-cultured with R848-stimulated MDCs, compared with those in other group of the treated podocytes (Figure 5F). These data indicate that TLR-7-activated MDCs can induce podocyte injury through ROS-activated p-38MAPK and NF-κB pathways.

Correlation of Podocyte Injury With Expansion of MDCs Is Verified in Pristane-Induced Lupus Mice

Pristane, an isoprenoid alkane induces a lupus-like syndrome in several non-autoimmune prone mouse strains (34). We constructed the pristane-induced lupus-prone mice and confirmed that the model mice showed significant renal damage. Consistent with the results of IMQ-treated mice, 7 months after pristane or PBS challenge, histologic sections were stained by PAS and analyzed for pathologic features. The results showed that glomerular injury with basement membrane thickening, mesangial matrix expansion, endocapillary hypercellularity, and PAS positive deposits in pristane-induced lupus mice (Figure 6A). Immunofluorescence staining of renal tissues showed that the number of WT-1+ and nephrin+ podocytes was significantly lower in the glomerular of pristane-treated mice than in PBS-treated mice (Figures 6B,C). Moreover, the results of electron microscopy revealed the exacerbated podocyte foot process effacement in pristane-treated mice compared with wild mice (Figure 6D). We also found that the expression levels of WT-1 and nephrin were significantly down-regulated in the kidneys of pristane-treated mice by qRT-PCR (Figure 6E). The above results suggest that pristane-induced lupus model mice encounter obvious renal damage, especially the glomerular podocyte injury. Of note, percentage
Figure 4 | Toll-like receptor-7 (TLR-7) activation induces myeloid-derived suppressor cells (MDSCs) to generate reactive oxygen species (ROS). (A) Expression of gp91phox and p47phox in MDSCs was measured by quantitative real-time RT-PCR (qRT-PCR) after 12 h treatment with R848 (10, 50, and 100 ng/ml); MDSCs treated with R848 for 24 h, loaded with DCFDA. Fluorescence intensity of DCFDA was measured by FACS. (B) Expression of arginase-1 in MDSCs was measured by QPCR after 12 h treatment with R848. (C) Expression of inducible nitric oxide synthase (iNOS) in MDSCs was measured by qRT-PCR after 12 h treatment with R848; NO in the supernatant of MDSCs was determined using NO detection kit after 24 or 48 h treatment with R848. (D) Expression of Wilms’ tumor protein (WT-1), nephrin, IL-1β, IL-6, and TNF-α in podocytes was measured by qRT-PCR after 24 h co-culture with treated R848 with MDSCs pretreated with N-acetyl-l-cysteine (NAC) for 1 h. (E) Expression of WT-1, nephrin, IL-1β, IL-6, and TNF-α in podocytes was measured by qRT-PCR after 24 h co-culture with treated R848 with MDSCs pretreated with NAC for 1 h. BM-derived MDSCs were pretreated with ROS inhibitors N-acetyl-l-cysteine (NAC, 5 mM) or iNOS inhibitors L-NMMA (0.5 mM) for 1 h, and co-cultured with mouse podocytes at ratio of 1:1 using transwell co-culture systems. Data represent the mean scores ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

**DISCUSSION**

Increasing studies suggest the expansion of MDSCs populations in murine models and patients with autoimmune diseases, especially SLE. These studies also indicate the association of MDSCs with the different degrees of LN in patient with SLE. A recent study demonstrated that expanded populations of both M-MDSCs and G-MDSCs and their frequency positively correlated with serum ARG1 concentration, Th17 cell responses and the associated renal injuries in patients with SLE and a SLE...
Myeloid-derived suppressor cells (MDSCs) induce podocyte injury by reactive oxygen species (ROS). BM-derived MDSCs were pretreated with ROS inhibitors N-acetyl-L-cysteine (5 mM) or inducible nitric oxide synthase inhibitors L-NMMA (0.5 mM) for 1 h, and co-cultured with mouse podocytes at ratio of 1:1 using transwell co-culture systems. (A) Representative light photomicrographs of podocytes after 48 h co-culture with MDSCs. (B) Expression of desmin in podocytes was measured by quantitative real-time RT-PCR after 24 h co-culture with MDSCs. (C,D) Podocyte apoptosis was assessed with annexin V by flow cytometry after 48 h co-culture with MDSCs (C) and the statistic results of podocyte apoptosis (D). Data represent the mean scores ± SEM. (E) The protein levels of p-p38, p-38, p-p65, and p-65 were assessed by western blot and normalized to GAPDH. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

According to previous results, a significant increase in MDSCs was positively correlated with renal injury in LN. Previously, we have already demonstrated that the expansion of splenic MDSCs and the degrees of renal injuries was increased with disease progression in SLE (13). In this study, we further confirmed significant renal injury symptoms, proteinuria, and the expansion of MDSCs in spleens and kidneys in both pristane and imiquimod-induced lupus-like model mice. These results suggested that MDSCs might be involved in the immune regulation of renal microenvironment and induce kidney lesions.

Podocytes are highly differentiated cells characterized by expressing markers, such as synaptopodin, Wilms’ tumor protein (WT-1), glomerular epithelial protein 1, and nephrin. These molecules play important roles to maintain filtration barrier integrity (35). In this study, we found the decreasing expression of WT-1 and nephrin by immunofluorescence and qRT-PCR in kidneys of both pristane and imiquimod-induced lupus-like model mice. These results indicated severe podocytes injury. Furthermore, we found the frequency of MDSCs was negatively correlated with the expression of WT-1 and nephrin in immunofluorescence and qRT-PCR in kidneys of both pristane and imiquimod-induced lupus-like model mice. These results indicated severe podocytes injury. Moreover, a number of studies demonstrated that LPS and oligosaccharide could cause comparable podocyte injury in vitro and in vivo (39). In the present study, TLR-7 activation of MDSCs occurred in kidneys of IMQ-treated mice and pristane-treated mice. Furthermore, ROS was increasing secreted by MDSCs stimulated with R848 and in vitro and in vivo. These results suggest that the role of TLR-7 activation is important in the generation of ROS of MDSCs. A common link of acute and chronic kidney injuries with the enhanced generation of ROS and reactive nitrogen species during injury progression was documented (40–42). Here, although the level of iNOS and NO was up-regulated in R848-treated MDSCs, the expression of WT-1 and nephrin was not significantly reversed in podocytes co-cultured with L-NMMA-pretreated MDSCs treated with R848, compared with podocytes co-cultured with R848-treated MDSCs. These data suggested that...
TLR-7-activated MDSCs promote podocyte injury mainly by the increased generation of ROS.

In the present study, we demonstrated that MDSCs induce podocytes injury by ROS and were involved in the subsequent development of proteinuria in LN for the first time. Furthermore, TLR-7-activated MDSCs enhanced podocyte injury through activating p-38MAPK and NF-kB pathways by ROS. In summary, our study further defined the role of MDSCs in the pathogenesis of LN, and we proposed that therapeutic approaches directed against MDSCs may lead to alleviation of the disease. In a word, our findings deepen our understanding of the occurrence of LN and provide a new ideas and targets for the clinical treatment of LN.

ETHICS STATEMENT

All aspects of this study were approved by the Research Ethics Committee of Nanjing University, and all experiments were conducted in accordance with institutional guidelines for animal care and used based on the Guide for the Animal Care Committee at Nanjing University. All these specimens were handled and anonymized according to ethical and legal standards.

AUTHOR CONTRIBUTIONS

DZ and JX conceived, designed the experiments, drafted the article, performed experiments, data analysis, and wrote the manuscript. JR, LD, GS, and DL supported the materials. YH provided the concept and designed this study. HD and YH co-designed experiments and co-wrote the manuscript. All authors reviewed and approved the manuscript final version.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (91542113 and 31570909) and supported by the Fundamental Research Funds for the Central Universities (021414380342).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.01443/full#supplementary-material.
REFERENCES

1. Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. *Front Immunol* (2015) 6:550. doi:10.3389/fimmu.2015.00550

2. Young S, Chan TM. Mechanisms of kidney injury in lupus nephritis – the role of anti-dsDNA antibodies. *Front Immunol* (2015) 6:475. doi:10.3389/fimmu.2015.00475

3. Borchers AT, Leibushor N, Nagawa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. *Autoimmun Rev* (2012) 12(2):174–94. doi:10.1016/j.autrev.2012.08.018

4. Davidson A. What is damaging the kidney in lupus nephritis? *Nat Rev Rheumatol* (2016) 12(3):143–53. doi:10.1038/nrrheum.2015.159

5. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathobiophysiologic subtypes. *Nat Rev Nephrol* (2017) 13(6):483–95. doi:10.1038/nrneph.2017.85

6. Zoller M. Janus-faced myeloid-derived suppressor cell exosomes for the good and the bad in cancer and autoimmune disease. *Front Immunol* (2018) 9:137. doi:10.3389/fimmu.2018.00137

7. Youn JJ, Nagaraj S, Collazo M, Gabrilovich D. Myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol* (2008) 181(6):5791–802. doi:10.4049/jimmunol.181.8.5791

8. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. *Nat Immunol* (2018) 19(2):108–19. doi:10.1038/s41591-017-0022-2

9. Pan MJ, Lee SH, Kim EK, Lee EI, Park SH, Kwok SK, et al. Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus. *Arthritis Rheumatol* (2016) 68(11):2717–27. doi:10.1002/art.39767

10. Fujiwara Y, Ashihara E, Hirai H, Nagahara H, Kajitani N, Fujioka K, et al. Prorenin receptor is essential for normal podocyte structure and function. *Lab Invest* (2015) 95(12):1374–86. doi:10.1038/labinvest.2015.118

11. Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. *Ann Rheum Dis* (2016) 75(1):278–85. doi:10.1136/annrheumdis-2014-200508

12. Ji J, Fan H, Li F, Li X, Dong G, Gong W, et al. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation. *Immunol Lett* (2015) 168(2):355–65. doi:10.1016/j.imlet.2015.10.017

13. Chen S, Wang L, Fan J, Ye C, Domiguez D, Zhang Y, et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. *Cancer Res* (2015) 75(3):519–31. doi:10.1158/0008-5472.CAN-14-2331

14. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JJ, Cheng P, et al. HIF-1a promotes the proliferation and differentiation of myeloid-derived suppressor cells within the tumor microenvironment. *J Exp Med* (2010) 207(11):2439–53. doi:10.1084/jem.20100587

15. Soni C, Wong EB, Domeier PP, Khan TN, Satoh T, Akira S, et al. Toll-like receptor 7 signaling is essential for the development of spontaneous germinal centers. *Nat Immunol* (2014) 15(9):4400–14. doi:10.4049/jimmunol.1401720

16. Theofilopoulos AN, Kono DH, Beutler B, Baccala R. Intracellular nucleic acid sensors and autoimmunity. *J Interferon Cytokine Res* (2011) 31(12):867–86. doi:10.1089/jir.2011.0082

17. Yokogawa M, Takashii M, Nakajima K, Kamijima R, Fujimoto C, Katoaka S, et al. Epigenetic manipulation of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus. *Arthritis Rheumatol* (2014) 66(6):694–706. doi:10.1002/art.38298

18. Funk J, Ott V, Herrmann A, Rapp W, Raab S, Bibolet E, et al. Semiautomated quantitative image analysis of glomerular immunohistochemistry markers desmin, vimentin, podocin, synaptopodin and WT-1 in acute and chronic renal disease models. *Histochim Cell Biol* (2016) 145(3):315–26. doi:10.1007/s00418-015-1391-6

19. Ishikawa T, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, et al. Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-D(y) mice. *Exp Diabetes Res* (2012) 2012:702948. doi:10.1155/2012/702948

20. Ros Santos M, Poletti PT, Milhoranta P, Monticello OA, Veronese FV. Unraveling the podocyte injury in lupus nephritis: clinical and experimental approaches. *Semin Arthritis Rheum* (2017) 46(5):632–41. doi:10.1016/j.semarthrit.2016.10.005

21. Lan X, Lederman R, Eng JM, Shoshtari SS, Saleem MA, Malhotra A, et al. Nicotine induces podocyte apoptosis through increasing oxidative stress. *PloS One* (2016) 11(12):e0167071. doi:10.1371/journal.pone.0167071

22. Wei M, Li Z, Xiao L, Yang Z. Effects of ROS-relative NF-kappaB signaling on type 2 diabetic KK-A(y) mice. *Exp Diabetes Res* (2012) 2012:702948. doi:10.1155/2012/702948

23. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. *Trends Immunol* (2009) 30(9):455–64. doi:10.1016/j.it.2009.06.003

24. Rezende GM, Viana VS, Malheiros DM, Borba EF, Silva NA, Silva C, et al. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria. *Kidney Int* (2014) 85(1):235–62. doi:10.1038/ki.2013.315

25. Horino T, Takao T, Morita T, Ito H, Hashimoto K. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. *Nephrol Dial Transplant* (2006) 21(1):230. doi:10.1093/ndt/gfh979

26. Sverrisson K, Axelsson J, Rippe A, Asgeirsson D, Rippe B. Acute reactive mineralocorticoid receptor-induced podocyte injury. *Lab Invest* (2015) 95(6):920–27. doi:10.4049/jimmunol.1500831

27. Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. *Kidney Int* (2006) 69(6):1213–47. doi:10.1038/sj.ki.5005410

28. Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. *Rheumatology* (2014) 53(7):1235–44. doi:10.1093/rheumatology/ket491

29. Cellesi F, Li M, Rastaldi MP. Podocyte injury and repair mechanisms. *Curr Opin Nephrol Hypertens* (2015) 24(3):239–44. doi:10.1097/MNH.0000000000000124

30. Fu R, Guo C, Wang S, Huang Y, Jin O, Hu H, et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. *Arthritis Rheumatol* (2017) 69(8):1636–46. doi:10.1002/art.40155

31. Yuan Y, Xu X, Zhao C, Zhao M, Wang H, Zhang B, et al. The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury. *Lab Invest* (2015) 95(12):1374–86. doi:10.1038/labinvest.2015.118
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhang, Xu, Ren, Ding, Shi, Li, Dou and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.